期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 166, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103453
关键词
BCMA; Neurotoxicity; Multiple myeloma; Chimeric antigen receptor therapy; Bispecific antibody; Antibody drug conjugate
BCMA has emerged as a key target in multiple myeloma treatment, with approved therapies showing unusual neurotoxicity possibly due to neural expression of BCMA. Further investigation is needed to understand and mitigate the risk of on-target toxicities associated with BCMA targeted therapies.
B-cell maturation antigen (BCMA) has become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already received regulatory approval in the United States. Although BCMA has generally been considered to be expressed almost exclusively in plasma cells with a low likelihood of on-target off-tumor toxicity, there has been a range of unusual neurotoxicity observed across the spectrum of BCMA immunotherapies. In certain cases, these unusual neurotoxicity presentations have led to patient death or withdrawal of agents from further development. Our review summarizes the literature in this field and highlights the possibility of on-target toxicities due to neural expression of BCMA. We draw attention to the need for further investigation of these toxicities. This risk becomes increasingly important as BCMA targeted therapies are brought to earlier lines of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据